VSGN - there was something to that run last week.
Globe/wire say Vasogen revives hopes for Celacade
Vasogen Inc (C:VAS)
Shares Issued 96,217,581
Last Close 9/1/2006 $0.65
Tuesday September 05 2006 - In the News
The Globe and Mail reports in a Reuters dispatch Monday a heart treatment from Vasogen, which failed a key clinical trial hurdle in June, still helped more than 70 per cent of patients, researchers said Sunday. Ben Hirschler of Reuters writes Vasogen chief executive officer David Elsley says he is confident the detailed analysis presented at the World Congress of Cardiology meant its Celacade therapy now had a promising commercial future. If all goes well, Celacade could go on sale in Europe around the middle of 2007. Further clinical studies will be needed before it is launched in the United States. Vasogen shares lost most of their value in June on news Celacade had not reached its primary goal of significantly reducing the overall risk of death and cardiovascular hospitalization in a 2,408-patient phase III clinical trial. But a review of the full data set released Sunday showed there was a 21-per-cent reduction in risk in a 1,746 patient subgroup that had not progressed to the more advanced stages of heart failure. Mr. Elsley said he was in advanced discussions with a number of potential partners that could market Celacade, initially in Europe, where the treatment already has a CE mark.
© 2006 Canjex Publishing Ltd.
--------------------------------------------------------------------------------
No virus found in this incoming message.
Checked by AVG Free Edition.
Version: 7.1.405 / Virus Database: 268.11.7/437 - Release Date: 9/4/06
Market Data 
Markets 
AI
